[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ITPD20030264A1 - Metodo di diagnosi altamente specifico per neoplasie - Google Patents

Metodo di diagnosi altamente specifico per neoplasie

Info

Publication number
ITPD20030264A1
ITPD20030264A1 IT000264A ITPD20030264A ITPD20030264A1 IT PD20030264 A1 ITPD20030264 A1 IT PD20030264A1 IT 000264 A IT000264 A IT 000264A IT PD20030264 A ITPD20030264 A IT PD20030264A IT PD20030264 A1 ITPD20030264 A1 IT PD20030264A1
Authority
IT
Italy
Prior art keywords
neoplasia
diagnosis method
highly specific
specific diagnosis
specific
Prior art date
Application number
IT000264A
Other languages
English (en)
Inventor
Luca Beneduce
Giorgio Fassina
Maria Marino
Patrizia Pontisso
Original Assignee
Xeptagen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xeptagen Spa filed Critical Xeptagen Spa
Priority to IT000264A priority Critical patent/ITPD20030264A1/it
Priority to EP04791917A priority patent/EP1678503B1/en
Priority to PCT/IT2004/000583 priority patent/WO2005043165A2/en
Priority to EP10178983A priority patent/EP2367005A1/en
Priority to EP10182565A priority patent/EP2339345A1/en
Priority to AT04791917T priority patent/ATE557276T1/de
Publication of ITPD20030264A1 publication Critical patent/ITPD20030264A1/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
IT000264A 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie ITPD20030264A1 (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IT000264A ITPD20030264A1 (it) 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie
EP04791917A EP1678503B1 (en) 2003-10-30 2004-10-26 Specific method for cancer detection
PCT/IT2004/000583 WO2005043165A2 (en) 2003-10-30 2004-10-26 Specific method for cancer detection
EP10178983A EP2367005A1 (en) 2003-10-30 2004-10-26 Method for measuring values indicating cancer
EP10182565A EP2339345A1 (en) 2003-10-30 2004-10-26 Method for measuring values indicating cancer
AT04791917T ATE557276T1 (de) 2003-10-30 2004-10-26 Spezifisches verfahren zum krebsnachweis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000264A ITPD20030264A1 (it) 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie

Publications (1)

Publication Number Publication Date
ITPD20030264A1 true ITPD20030264A1 (it) 2005-04-30

Family

ID=34531934

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000264A ITPD20030264A1 (it) 2003-10-30 2003-10-30 Metodo di diagnosi altamente specifico per neoplasie

Country Status (4)

Country Link
EP (3) EP2339345A1 (it)
AT (1) ATE557276T1 (it)
IT (1) ITPD20030264A1 (it)
WO (1) WO2005043165A2 (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
AU2006315348A1 (en) * 2005-11-16 2007-05-24 Beth Israel Deaconess Medical Center Method to assess breast cancer risk
ES2363891T3 (es) 2006-03-20 2011-08-18 The Regents Of The University Of California Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US9562905B2 (en) * 2009-07-29 2017-02-07 Radox Laboratories Limited Method for detection of, or the risk of, bladder cancer
EP3511023A1 (en) 2009-12-02 2019-07-17 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20120295814A1 (en) * 2010-01-08 2012-11-22 The Brigham And Women's Hospital, Inc. CA-125 Immune Complexes as Biomarkers of Ovarian Cancer
KR20140034124A (ko) * 2010-12-06 2014-03-19 티에이치디 에스.피.에이. 암종의 진단방법 및 그의 용도
US20140038838A1 (en) 2012-06-27 2014-02-06 Niven Rajin Narain Use of markers in the diagnosis and treatment of prostate cancer
GB201218570D0 (en) 2012-10-16 2012-11-28 Randox Lab Ltd Method
EP3102947B1 (en) 2014-02-04 2018-11-14 CellTrend GmbH Diagnosis of cancer by detecting auto-antibodies against par1
WO2015117953A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (vegf)
WO2015117951A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against egf-receptor
EP3102945B1 (en) * 2014-02-04 2018-10-17 CellTrend GmbH Diagnosis of cancer by detecting auto-antibodies against epidermal growth factor (egf)
WO2015117955A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against vascular endothelialgrowth factor receptor (vegfr)
CN104062437A (zh) * 2014-06-12 2014-09-24 上海交通大学医学院附属瑞金医院 Erbb2蛋白在制备检测嗜铬细胞瘤转移试剂中的应用
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
NZ739721A (en) 2015-08-07 2019-09-27 Imaginab Inc Antigen binding constructs to target molecules
WO2017201225A1 (en) * 2016-05-19 2017-11-23 Poc Medical Systems, Inc. Cancer screening via detection and quantification of multiple biomarkers
CN106468711A (zh) * 2016-09-07 2017-03-01 北京热景生物技术股份有限公司 Dcp快速分离检测试剂盒
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5915858A (ja) * 1982-07-16 1984-01-26 Otsuka Pharmaceut Co Ltd 腫瘍関連抗原特異的免疫複合体の測定法
US4711839A (en) * 1985-01-11 1987-12-08 Imre Corporation Immune complex assay
EP0529007A1 (en) * 1990-04-18 1993-03-03 The Regents Of The University Of California A 35kD TUMOR ASSOCIATED PROTEIN ANTIGEN: USES AND METHODS OF DETECTION
AU5362094A (en) * 1992-10-14 1994-05-09 Scripps Research Institute, The Methods for the detection of antigen-specific immune complexes
AU2001247722A1 (en) * 2000-03-27 2001-10-08 Diagen Corporation Antigen-specific enzyme-linked immunosorbent assay
IT1317355B1 (it) * 2000-07-28 2003-06-16 Xeptagen S R L Anticorpi policlonali.

Also Published As

Publication number Publication date
ATE557276T1 (de) 2012-05-15
EP1678503A2 (en) 2006-07-12
EP2367005A1 (en) 2011-09-21
WO2005043165A3 (en) 2005-08-04
EP1678503B1 (en) 2012-05-09
WO2005043165A2 (en) 2005-05-12
EP2339345A1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
ITPD20030264A1 (it) Metodo di diagnosi altamente specifico per neoplasie
CY1112631T1 (el) ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE551367T1 (de) Epha2-bindende antikörper und verfahren zu ihrer verwendung
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE60214134D1 (de) Modifizierte psma-liganden und deren verwendung
NO20084546L (no) Diagnostikk og behandlinger for tumorer
MA30654B1 (fr) Therapie tumorale avec anticorps anti-vegf
CY1112953T1 (el) Χρηση των αντι-cd100 αντισωματων
DK2135881T3 (da) Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
CY1109421T1 (el) ΔΟΣΕΙΣ ΓΙΑ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
PL2097453T3 (pl) Przeciwciała monoklonalne przeciw ludzkiemu receptorowi hormonu anty-Mullerowskiego typu II (AMHR-II)
ATE424560T1 (de) Marker für neuromyelitis optica
NL1026220A1 (nl) Stationair computertomografiesysteem met compact röntgenstralenbron-samenstel.
ATE414535T1 (de) Trägerproteine für impfstoffe
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
DE602005008787D1 (de) Nahrungsmittelanalysator für autonom angetriebene Futterstationen, sowie Verfahren dafür
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
EP2267450A3 (en) Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
EA200800948A1 (ru) Биотиндиаминопроизводные и их конъюгаты с макроциклическими хелатирующими реагентами
AT500651B1 (de) Aktiv immunisierender antikörper
WO2003024302A3 (en) Detection and treatment of cancers of breast